<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02394132</url>
  </required_header>
  <id_info>
    <org_study_id>02.12</org_study_id>
    <nct_id>NCT02394132</nct_id>
  </id_info>
  <brief_title>Radiotherapy or Imiquimod in Complex Lentigo Maligna</brief_title>
  <acronym>RADICAL</acronym>
  <official_title>A Randomised Controlled Multicentre Trial of Imiquimod Versus Radiotherapy for Lentigo Maligna (LM) When Staged Surgical Excision With 5mm Margins is Not Possible, is Refused, or Fails</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Melanoma and Skin Cancer Trials Limited</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Melanoma Institute Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Melanoma and Skin Cancer Trials Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effectiveness of using either radiotherapy&#xD;
      (RT) or Imiquimod (ImiQ) to treat the Lentigo Maligna (LM), when surgery is not possible, is&#xD;
      refused, or fails.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Surgery is the standard treatment for people diagnosed with LM. However for some people, it&#xD;
      may not be possible due to the location of their LM lesion(s).&#xD;
&#xD;
      Currently, the Australian and New Zealand Melanoma Treatment Guidelines recommend&#xD;
      radiotherapy for the treatment of LM however there is no clinical trial evidence for this and&#xD;
      a trial is needed to prove which treatment is safer and more effective. Some clinicians may&#xD;
      also recommend the use of a cream called Imiquimod. It is approved and widely used in&#xD;
      Australia to treat solar keratosis, superficial basal cell carcinoma, external genital warts,&#xD;
      and perianal warts. Although not currently licensed for treatment use in LM, there is some&#xD;
      evidence to suggest that it is both safe and effective in treating LM.&#xD;
&#xD;
      This trial will scientifically evaluate and compare these two treatments in a controlled&#xD;
      clinical setting.&#xD;
&#xD;
      The primary objective of this trial is to compare the rate of LM treatment failure and&#xD;
      recurrence rate measured at 24 months (primary endpoint), and measured at 6, 12 months&#xD;
      (secondary endpoints) following treatment with ImiQ or RT. For this study, treatment failure&#xD;
      includes both the recurrence and persistence of LM, and is defined as the presence of LM&#xD;
      cells within the original field of treatment confirmed by histopathology.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2015</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients experiencing LM treatment failure (as determined by systematic biopsy) 6 months following completion of treatment.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>LM treatment failure at 12 months and 24 months after the completion of treatment.</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life using Skindex questionnaire</measure>
    <time_frame>0-24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cosmetic outcome 24 months after treatment or at treatment failure</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluated using photographs taken of LM lesion(s) during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of invasive melanoma within treatment fields; a sub-study to evaluate the utility of reflectance confocal microscopy (RCM) compared with standard biopsy in diagnosing recurrence</measure>
    <time_frame>0-24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Lentigo Maligna</condition>
  <arm_group>
    <arm_group_label>Imiquimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical imiquimod 5% cream&#xD;
application to treatment area for 5 days/week for a total of 12 weeks&#xD;
dispensed at baseline visit along with patient diary</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy&#xD;
treatment regimen determined by treating radiation oncologist and as per standard practice at local institution&#xD;
treatment to commence within 8 weeks of randomisation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod</intervention_name>
    <arm_group_label>Imiquimod</arm_group_label>
    <other_name>Aldara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <arm_group_label>Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18 years or older.&#xD;
&#xD;
          2. A biopsy-proven LM. This includes previous treatment failures (not with imiquimod or&#xD;
             RT) of LM that are diagnosed as biopsy-proven LM.&#xD;
&#xD;
          3. LM that is in a location amenable to treatment with imiquimod and radiotherapy.&#xD;
&#xD;
          4. Willing and able to comply with study requirements.&#xD;
&#xD;
          5. Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Invasive melanoma.&#xD;
&#xD;
          2. Medical or psychiatric condition that compromises the ability of the patient to&#xD;
             complete protocol treatment or follow-up assessments.&#xD;
&#xD;
          3. Patients who are pregnant or lactating. Women of child bearing potential must have a&#xD;
             confirmed negative urine pregnancy test at study entry.&#xD;
&#xD;
          4. Life expectancy of less than 2 years.&#xD;
&#xD;
          5. Radiotherapy sensitivity syndrome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascale Guitera</last_name>
    <role>Principal Investigator</role>
    <affiliation>Melanoma Institute Australia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melanoma and Skin Cancer Trials Coordinator</last_name>
    <phone>+61 3 9903 9022</phone>
    <email>radical@masc.org.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Calvary Mater Newcastle</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Wratten</last_name>
    </contact>
    <investigator>
      <last_name>Chris Wratten</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Melanoma Institute Australia</name>
      <address>
        <city>North Sydney</city>
        <state>New South Wales</state>
        <zip>2060</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascale Guitera</last_name>
    </contact>
    <investigator>
      <last_name>Pascale Guitera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skin and Cancer Foundation</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Fernandez-Penas</last_name>
    </contact>
    <investigator>
      <last_name>Pablo Fernandez Penas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Fernandez-Penas</last_name>
    </contact>
    <investigator>
      <last_name>Pablo Fernandez Penas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital, Sydney</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald Fogarty</last_name>
    </contact>
    <investigator>
      <last_name>Gerald Fogarty</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Soyer</last_name>
    </contact>
    <investigator>
      <last_name>Peter Soyer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shireen Sidhu</last_name>
    </contact>
    <investigator>
      <last_name>Shireen Sidhu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Mar</last_name>
    </contact>
    <investigator>
      <last_name>Victoria Mar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas, University of Sao Paulo</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lilian Rocha</last_name>
    </contact>
    <investigator>
      <last_name>Lilian Rocha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Shore Hospital</name>
      <address>
        <city>Takapuna</city>
        <state>Auckland</state>
        <zip>0740</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Martin</last_name>
    </contact>
    <investigator>
      <last_name>Richard Martin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 10, 2015</study_first_submitted>
  <study_first_submitted_qc>March 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2015</study_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lentigo maligna</keyword>
  <keyword>Imiquimod</keyword>
  <keyword>Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hutchinson's Melanotic Freckle</mesh_term>
    <mesh_term>Lentigo</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

